Robinson James A. Jr. 4

What Happened

• James A. Robinson Jr., a director of UroGen Pharma Ltd. (URGN), had derivative awards convert on 2025-02-26: 2,000 units were exercised/converted into shares (acquired) and a corresponding 2,000 units were recorded as disposed at $0.00. The filing identifies these as restricted stock units (RSUs) — each RSU is a contingent right to one ordinary share (footnote F1).
• No cash open‑market sale is reported; the $0.00 disposition likely reflects withholding, surrender, or internal settlement rather than a market sale. This type of transaction is typically routine (e.g., vesting and tax withholding), not a purchase that signals bullish conviction.

Key Details

• Transaction date: 2025-02-26. Prices reported: acquisition N/A (conversion), disposition $0.00 (total value $0).
• Shares owned after the transaction: not specified in the excerpt provided — see the full Form 4 for post-transaction holdings.
• Notable footnote: F1 — each RSU equals a contingent right to one ordinary share.
• Timing/filing note: the Form 4 was filed 2026-02-27 for a 2025-02-26 transaction; this appears to be a late filing. Check the full SEC filing for any explanations or corrective disclosures.

Context

• For derivative/RSU conversions: the record shows conversion of RSUs into shares and an immediate disposition at $0, which commonly reflects tax withholding or share surrender rather than a market sale. There is no indication shares were sold on the open market.
• For investors: conversions and withholding are routine insider events. If you track insider sentiment, purchases or open-market sales are typically more informative; consult the full Form 4 for ownership totals and any issuer/insider comments.